Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 19, 2017
What is the competitive landscape for JANSSEN PRODS, and when can generic versions of JANSSEN PRODS drugs launch?
JANSSEN PRODS has six approved drugs.| Patents: | 25 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 6 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
darunavir ethanolate | Tablets | 800 mg | PREZISTA | 5/14/2013 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,486,942 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||||||||||||||||
| 8,088,770 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||||||||||||||||
| 7,956,063 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl- ]amino]benzonitrile | ► Subscribe | |||||||||||||||||||||||||||
| 9,139,541 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||||||||||||||||
| 9,580,392 | HIV replication inhibiting pyrimidines | ► Subscribe | |||||||||||||||||||||||||||
| 8,067,449 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||||||||||||||||
| 8,383,655 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||||||||||||||||
| 8,841,310 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 7,608,590 | HCV NS-3 serine protease inhibitors | ► Subscribe | |||||||||||||||||||||||||||
| 8,153,800 | Macrocyclic inhibitors of hepatitis C virus | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | 102018714 | ► Subscribe | |||||||||||||||||||||||||||
| Croatia | P20100048 | ► Subscribe | |||||||||||||||||||||||||||
| Lithuania | PA2016043 | ► Subscribe | |||||||||||||||||||||||||||
| Denmark | 1663240 | ► Subscribe | |||||||||||||||||||||||||||
| African Regional IP Organization (ARIPO) | 200703934 | ► Subscribe | |||||||||||||||||||||||||||
| Hong Kong | 1053783 | ► Subscribe | |||||||||||||||||||||||||||
| Serbia | 51743 | ► Subscribe | |||||||||||||||||||||||||||
| Lithuania | PA2016042 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 101284361 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 2017001 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0140034 00151 | Estonia | ► Subscribe | PRODUCT NAME: SIMEPREVIIR;REG NO/DATE: EU/1/14/924 16.05.2014 | ||||||||||||||||||||||||||
| 5 5007-2012 | Slovakia | ► Subscribe | PRODUCT NAME: RILPIVIRIN; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 | ||||||||||||||||||||||||||
| 2015038 | Lithuania | ► Subscribe | PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128 | ||||||||||||||||||||||||||
| 2 5010-2012 | Slovakia | ► Subscribe | PRODUCT NAME: RILPIVIRINHYDROCHLORID/TENOFOVIRDIZOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 | ||||||||||||||||||||||||||
| 00532 | Netherlands | ► Subscribe | PRODUCT NAME: EEN COMBINATIE VAN RILPIVIRINE EN ELKE DOOR HET BASISOCTROOI BESCHERMDE THERAPEUTISCH EQUIVALENTE VORM DAARVAN,; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 | ||||||||||||||||||||||||||
| 90064-1 | Sweden | ► Subscribe | PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 | ||||||||||||||||||||||||||
| 2016000109 | Germany | ► Subscribe | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN, DURCH DAS GRUNDPATENT GESCHUETZTEN FORM DAVON, Z.B. EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN. EMTRICITABIN UND TENOFOVIRALAFENAMID ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/16/1112 20160621 | ||||||||||||||||||||||||||
| 12/017 | Ireland | ► Subscribe | PRODUCT NAME: RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT THEREOF, INCLUDING THE HYDROCHLORIC ACID SALT OF RILPIVIRINE; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 | ||||||||||||||||||||||||||
| 2 6-2015 | Slovakia | ► Subscribe | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 | ||||||||||||||||||||||||||
| 2016000120 | Germany | ► Subscribe | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCHES AKZEPTABLES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE ATAZANAVIRSULFAT; REGISTRATION NO/DATE: EU/1/15/1025 20150713 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,662 others who get our Drug Patent Expiration Alerts:
